Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Allarity Therapeutics, Inc.ALLR · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $18.3M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | late filer, thin datanot computable: distress, fortress balance sheet |
| Inputs computable | 5 of 14 |
| Graded from | filings received through Mar 30, 2026193 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $1.002026-10-07; market equity $15.9M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.
We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell’s sensitivity to a specific cancer therapeutic.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 94.7 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| required facts have no common fiscal period end | |||||||
| Accruals ratio | 17.5% | [1,3-5] | (6.6%) | 94.7 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 72.7 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (23.25) | [1,6-11] | (0.31) | 76.0 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| required facts have no common fiscal period end | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 2.13x | [6-7] | 2.96x | 69.5 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 18.4 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 1 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| four consecutive annual FCF observations are required; found 3 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | 7.9% | [1,5,12-13] | 2.1% | 35.0 | 704 | 2025-12-31 | |
| Net share issuance, one year | (7.0%) | [14-15] | 2.5% | 1.9 | 634 | 2026-03-30 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-07 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (10.8%) | 8.0% | 39 | hotter than 39 of 100 peers |
| Distance from 52-week high | (44.5%) | (31.4%) | 33 | closer to its high than 33 of 100 peers |
| EBIT to enterprise value | (949.4%) | (1.5%) | 2 | pricier than 98 of 100 peers |
| Free cash flow yield | (94.9%) | (1.0%) | 5 | pricier than 95 of 100 peers |
| Book value to price | 0.23 | 0.28 | 44 | pricier than 56 of 100 peers |
| Sales to price | 0.02 | 0.31 | 9 | pricier than 91 of 100 peers |
| Composite equity issuance, five years | not computable | 20.3% | a share count from five years earlier is required | |
| Relative strength against the sector, log excess return | (0.33) | (0.14) | 39 | ahead of 39 of 100 peers |
Inputs: market equity $15.6M; EBIT -$12.6M; free cash flow -$14.8M; book equity $3.5M; sales $320,000; debt $2.7M; cash $17.0M[16].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (49.6%) | ✗ fail[3,5] |
| Operating cash flow above zero | -$14.8M | ✗ fail[4] |
| Return on assets improved | 157.1 pts | ✓ pass[3,5,12,17] |
| Operating cash flow exceeds net income | -$3.6M | ✗ fail[3-4] |
| Long-term leverage fell | n/a[1,5,12] | |
| Current ratio improved | 6.6 pts | ✓ pass[6-7,18-19] |
| No new shares issued | (7.0%) | ✓ pass[14-15] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[2,5,12] | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $17.0M[20] |
| Operating cash flow, four quarters | -$13.7M[4,20-24] |
| Months of runway | 14.9 |
| Late filings, two years | 1 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 56 |
| 10-Q received Aug 14, 2026 | |
| Median daily dollar volume | $82,539 |
| 63 sessions | |
| Days since newest grade input | 193 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $18.3M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax | $320,000 | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 3 | net income | us-gaap:NetIncomeLoss | -$11.2M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$14.8M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 5 | assets | us-gaap:Assets | $22.6M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 6 | current assets | us-gaap:AssetsCurrent | $17.9M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 7 | current liabilities | us-gaap:LiabilitiesCurrent | $8.4M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 8 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$130.2M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 9 | operating income | us-gaap:OperatingIncomeLoss | -$12.6M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 10 | book equity | us-gaap:StockholdersEquity | $9.8M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 11 | liabilities | us-gaap:Liabilities | $8.4M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 12 | assets | us-gaap:Assets | $11.9M | 2023-12-31 | 2025-03-31 | 10-K | filing · viewer · series |
| 13 | assets | us-gaap:Assets | $14.5M | 2022-12-31 | 2024-03-08 | 10-K | filing · viewer · series |
| 14 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 15,818,980 | 2026-03-30 | 2026-03-30 | 10-K | filing · viewer · series |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 17,014,737 | 2025-03-31 | 2025-03-31 | 10-K | filing · viewer · series |
| 16 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 15,910,724 | 2026-08-14 | 2026-08-14 | 10-Q | filing · viewer · series |
| 17 | net income | us-gaap:NetIncomeLoss | -$24.5M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 18 | current assets | us-gaap:AssetsCurrent | $22.3M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 19 | current liabilities | us-gaap:LiabilitiesCurrent | $10.8M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 20 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $17.0M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$7.1M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$4.5M | 2026-03-31 | 2026-05-15 | 10-Q | filing · viewer · series |
| 23 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$11.6M | 2025-09-30 | 2025-11-14 | 10-Q | filing · viewer · series |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.2M | 2025-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.